Targacept regains selected rights as part of rejigged AstraZeneca alliance
This article was originally published in Scrip
Executive Summary
Targacept's upbeat spin on its renegotiated collaboration agreement with AstraZeneca for the development of drugs that selectively target neuronal nicotinic receptors (NNRs) kept the US company's stock in positive territory on 5 March.